Unlocking the potential of the cell membrane

At Providentia, we're unlocking the cell membrane as a new frontier in drug discovery. For decades, drug development has focused almost entirely on genes and proteins — leaving the cell membrane, one of the most dynamic and least understood parts of a cell, largely untapped.

Our proprietary Synthetic Cell Membrane Screen quantifies how a drug changes the physical properties of the cell membrane, in real time. This is a novel data layer that no one else can generate. This matters because many drug targets (ion channels and GPCRs) are proteins embedded in the membrane, and their behavior depends on that membrane environment. 

We've used this platform to build a growing, first-of-its-kind dataset of drug-membrane interactions, and we train proprietary AI on top of it to decode what's driving those effects.

That data layer already powers one capability: predicting a drug's toxicity earlier and at lower cost than industry-standard methods, without the need for live cells. 

We're now developing a second: using our AI to modify a molecule's structure to reduce that toxicity before it ever reaches costly, later-stage testing.

Looking ahead, we're using this same platform to design an entirely new class of medicines: therapeutics that target the cell membrane directly. Our early pipeline spans some of the most urgent areas in medicine today, including cancer, neurodegenerative disease, heart disease, and aging.